López-Iglesias and colleagues demonstrated that tinostamustine has a potent activity in MM cell lines and ex vivo in cells isolated from MM patients, which was higher than that of bendamustine and this activity was confirmed in vivo, in a CB17-SCID murine plasmacytoma model and in de novo Vk*MYC mice, leading to a significant survival improvement in both models [173]. This evidence concerns the gene MYC and Miyoshi myopathy.